IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. TAP
3. DELL
4. ROIV
5. ANET
6. NKE
7. PANW
8. CL
9. SNDK
10. SPG

Go back to IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
(NASDAQ: IMNN) Delayed: 1.58 +0.02 (1.28%)
Previous Close $1.56    52 Week High $ 
Open $1.56    52 Week Low $ 
Day High $1.58    P/E N/A 
Day Low $1.54    EPS $ 
Volume 34,012